Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to estimate the control rate (CR,PR,SD) of docetaxel and
irinotecan (DI) combination chemotherapy for recurrent or refractory bone and soft tissue
sarcomas.Al so, this study is to evaluate the toxicity profile of Docetaxel and Irinotecan
(DI) combination chemotherapy.